search
Back to results

Dexmedetomidine for Prophylaxis Against PONV in Highly Susceptible Patients.

Primary Purpose

Postoperative Nausea and Vomiting, Head and Neck Surgeries

Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Dexmedetomidine Hydrochloride 0.5 mic/kg bolus
Dexmedetomidine Hydrochloride 0.75 mic/kg bolus
Placebo
Sponsored by
Cairo University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Postoperative Nausea and Vomiting focused on measuring Dexmedetomidine, PONV, ondansetron, post operative, nausea, vomiting

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Two risk factors or more for PONV ( female, non-smoking, postoperative opioids, history of motion sickness or PONV )
  • Head and neck surgeries in adults
  • ASA ( I , II )

Exclusion Criteria:

  • Patients on ( steroids , antiemetics or any drug caude emesis )
  • Any active cardiac condition at the time of the surgery
  • Pregnancy

Sites / Locations

  • Cairo University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Dexmedetomidine 0.5 mic/kg bolus

dexmedetomidine 0.75 mic/kg bllus

Placebo group

Arm Description

selective alpha 2 adrenergic receptor agonist

selective alpha 2 adrenergic receptor agonist

receving equal volume of normal saline

Outcomes

Primary Outcome Measures

Incidence of PONV in the 1st 24 hours postoperatively
The overall incidence of nausea and vomiting in the 1st 24 hours following Head and neck surgeries.

Secondary Outcome Measures

Number of PONV attacks
Number of PONV attacks in the 1st 24 hours following Head and neck surgeries
Pain score postoperatively.
Pain assessement using visual analogous scale score (0-10) with 10 denoting the worst pain expressed and zero= no pain
Sedation score
using Observer's assessment of ALERTNESS and Sedation (1-5)with 1 = unconscious and 5= Alert
Patient satisfaction
The patient completes a simple questionnaire with 0= very satisfied 1 = satisfied 2= not satisfied
Blood pressure
Mean arterial blood pressure (MAP) in the 1st 24 hours
Heart Rate (HR)
Pulse rate in the 1st 24 hours
The time to 1st call for rescue antiemetic
time to 1st call for rescue antiemetic and the severity of nausea ( using the 11 verbal 11-point rating scale 0= no nausea 10= the worst nausea
The severity of nausea.
the severity of nausea ( using the 11 verbal 11-point rating scale 0= no nausea 10= the worst nausea
Total amount of morphine consumption
morphine consumed in thw 1st 24 hours in milligrams.
The time to 1st call for rescue analgesia
time to 1st call for rescure analgesic medication in the 1st 24 hours postoperatively

Full Information

First Posted
October 30, 2021
Last Updated
August 28, 2023
Sponsor
Cairo University
search

1. Study Identification

Unique Protocol Identification Number
NCT05134363
Brief Title
Dexmedetomidine for Prophylaxis Against PONV in Highly Susceptible Patients.
Official Title
Dexmedetomidine for Prophylaxis Against Postoperative Nausea and Vomiting in Highly Susceptible Patients: a Randomised Controlled Comparison of Two Bolus Doses
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
August 11, 2021 (Actual)
Primary Completion Date
June 20, 2023 (Actual)
Study Completion Date
June 20, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study aims to compare between two bolus doses of dexmedetomidine in preventing PONV in highly susceptible patients.
Detailed Description
Being A challenging complaint, many studies tried to find an effective preventive strategies for PONV. In this study protocol the investigators aim to compare between 0.5 mic/kg and 0.75 mic/kg bolus doses of dexmedetomidine when given toward the end of head and neck surgeries in highly susceptible patients with a controlled group receiving ondansetron. The primary outcome is the 1st 24 hours incidence of PONV Other outcomes include: Time to 1st call for rescue antiemetic and the total amount of antiemetics Number of PONV attacks Post operative pain score with visual analogous scale (VAS) and time to 1st call for rescue analgesia Sedation Score using Observer's Assessment of Alertness and sedation (OAA/S) Patient satisfaction Vital signs in the 1st 24 hours

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Nausea and Vomiting, Head and Neck Surgeries
Keywords
Dexmedetomidine, PONV, ondansetron, post operative, nausea, vomiting

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
comparative study between two doses and a 3rd control group
Masking
Investigator
Allocation
Randomized
Enrollment
180 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dexmedetomidine 0.5 mic/kg bolus
Arm Type
Active Comparator
Arm Description
selective alpha 2 adrenergic receptor agonist
Arm Title
dexmedetomidine 0.75 mic/kg bllus
Arm Type
Active Comparator
Arm Description
selective alpha 2 adrenergic receptor agonist
Arm Title
Placebo group
Arm Type
Placebo Comparator
Arm Description
receving equal volume of normal saline
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine Hydrochloride 0.5 mic/kg bolus
Intervention Description
comparison between two bolus doses of dexmedetomidine with a placebo group
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine Hydrochloride 0.75 mic/kg bolus
Intervention Description
comparison between two bolus doses of dexmedetomidine with a conventional group receiving ondansetron.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
equal volume of normal saline
Primary Outcome Measure Information:
Title
Incidence of PONV in the 1st 24 hours postoperatively
Description
The overall incidence of nausea and vomiting in the 1st 24 hours following Head and neck surgeries.
Time Frame
The first 24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )
Secondary Outcome Measure Information:
Title
Number of PONV attacks
Description
Number of PONV attacks in the 1st 24 hours following Head and neck surgeries
Time Frame
The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )
Title
Pain score postoperatively.
Description
Pain assessement using visual analogous scale score (0-10) with 10 denoting the worst pain expressed and zero= no pain
Time Frame
The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )
Title
Sedation score
Description
using Observer's assessment of ALERTNESS and Sedation (1-5)with 1 = unconscious and 5= Alert
Time Frame
The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )
Title
Patient satisfaction
Description
The patient completes a simple questionnaire with 0= very satisfied 1 = satisfied 2= not satisfied
Time Frame
The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )
Title
Blood pressure
Description
Mean arterial blood pressure (MAP) in the 1st 24 hours
Time Frame
The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )
Title
Heart Rate (HR)
Description
Pulse rate in the 1st 24 hours
Time Frame
The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )
Title
The time to 1st call for rescue antiemetic
Description
time to 1st call for rescue antiemetic and the severity of nausea ( using the 11 verbal 11-point rating scale 0= no nausea 10= the worst nausea
Time Frame
In the 1st 24 hours
Title
The severity of nausea.
Description
the severity of nausea ( using the 11 verbal 11-point rating scale 0= no nausea 10= the worst nausea
Time Frame
The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )
Title
Total amount of morphine consumption
Description
morphine consumed in thw 1st 24 hours in milligrams.
Time Frame
The first24 hours ( every half an hour in the 1st 2 hours and then at 4,6,8,12 and 24 hours )
Title
The time to 1st call for rescue analgesia
Description
time to 1st call for rescure analgesic medication in the 1st 24 hours postoperatively
Time Frame
In the first 24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Two risk factors or more for PONV ( female, non-smoking, postoperative opioids, history of motion sickness or PONV ) Head and neck surgeries in adults ASA ( I , II ) Exclusion Criteria: Patients on ( steroids , antiemetics or any drug caude emesis ) Any active cardiac condition at the time of the surgery Pregnancy
Facility Information:
Facility Name
Cairo University
City
Cairo
ZIP/Postal Code
11511
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
10485781
Citation
Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999 Sep;91(3):693-700. doi: 10.1097/00000542-199909000-00022.
Results Reference
background
PubMed Identifier
23698545
Citation
Kim SH, Oh YJ, Park BW, Sim J, Choi YS. Effects of single-dose dexmedetomidine on the quality of recovery after modified radical mastectomy: a randomised controlled trial. Minerva Anestesiol. 2013 Nov;79(11):1248-58. Epub 2013 May 23.
Results Reference
result

Learn more about this trial

Dexmedetomidine for Prophylaxis Against PONV in Highly Susceptible Patients.

We'll reach out to this number within 24 hrs